NCT03671616View on ClinicalTrials.gov

Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months

PHASE3CompletedINTERVENTIONAL
Enrollment

666

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

October 3, 2018

Study Completion Date

October 3, 2018

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

IPV-Al SSI

IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.

Trial Locations (1)

0816-00383

Cevaxin, Panama City

Sponsors

Collaborators (1)

AJ Vaccines A/S
All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Larix A/S

INDUSTRY

collaborator

Vaxtrials S.A.

OTHER

collaborator

AJ Vaccines A/S

INDUSTRY

lead

Statens Serum Institut

OTHER

NCT03671616 - Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months | Biotech Hunter | Biotech Hunter